BAY X 1005

Drug Profile

BAY X 1005

Latest Information Update: 20 Feb 2006

Price : $50

At a glance

  • Originator Bayer
  • Class Antiallergics; Antiasthmatics; Quinolines; Small molecules
  • Mechanism of Action 5-lipoxygenase activating protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Asthma; Bronchitis; Chronic obstructive pulmonary disease; Ischaemic heart disorders; Rheumatoid arthritis

Most Recent Events

  • 12 Aug 2002 A clinical study has been added to the Respiratory Tract Disorders pharmacodynamics section
  • 07 Jun 2000 No-Development-Reported for Asthma in USA (PO)
  • 07 Jun 2000 No-Development-Reported for Asthma in Germany (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top